Research progress in CD46 in cancer immunotherapy
10.3760/cma.j.cn112309-20240627-00231
- VernacularTitle:CD46在肿瘤免疫治疗中的研究进展
- Author:
Ziyi YAN
1
;
Huihui XU
1
Author Information
1. 温州医科大学附属台州医院中心实验室，台州 317000
- Publication Type:Journal Article
- Keywords:
Tumor;
CD46;
Immunotherapy
- From:
Chinese Journal of Microbiology and Immunology
2025;45(10):891-896
- CountryChina
- Language:Chinese
-
Abstract:
CD46 is a type Ⅰ transmembrane glycoprotein that participates in the classical pathway and alternative complement activation cascade in the innate immune system. CD46 is highly expressed on the surface of various tumor cells，playing a significant role in promoting tumor progression and immune evasion. Studies have found that the expression level of CD46 is closely related to the prognosis and immunotherapy outcomes of multiple tumors. Inhibition of CD46 expression or function can enhance the sensitivity of tumor cells to oncolytic adenovirus therapy，among others. However，the clinical application of CD46 in tumor immunotherapy still faces some challenges. This review summarizes the research progress in CD46 in tumor immunotherapy，aiming to further explore the mechanisms of CD46 and the clinical potential of potential therapeutic targets.
